胆固醇检测市场－全球产业规模、份额、趋势、机会和预测，按产品类型、按检测类型、按处方模式、按最终用户、按地区和竞争细分，2020-2030 年

2024年全球胆固醇检测市场规模达123.6亿美元，预计在预测期内将呈现强劲成长，到2030年的复合年增长率为6.92%。胆固醇检测，也称为血脂谱或血脂组，是一项重要的医学检查，用于评估血液中各种脂质（主要是胆固醇和三酸甘油酯）的水平。此检测通常测量总胆固醇、低密度脂蛋白（LDL，即「坏」胆固醇）、高密度脂蛋白（HDL，即「好」胆固醇）和三酸甘油酯。这些数值有助于了解一个人的心血管健康状况，并有助于识别冠状动脉疾病、心臟病发作和中风等疾病的潜在风险。 LDL水平升高和HDL水平降低会增加动脉斑块积聚的风险，导致血流受限和严重的心臟併发症。对于有心臟病家族史、糖尿病患者或久坐不动且饮食习惯不良的人来说，常规胆固醇检测尤其重要。及早发现胆固醇水平异常，有助于及时改变生活方式或采取医疗干预措施，例如采用更健康的饮食、增加体能活动或服用降胆固醇药物。由于胆固醇水平受多种因素影响，包括年龄、遗传、饮食和整体健康状况，因此咨询医疗保健专业人员至关重要。他们可以准确解读结果，并建议个人化的胆固醇管理策略，以维持长期心血管健康。

关键市场驱动因素

心血管疾病盛行率上升

主要市场挑战

技术限制

主要市场趋势

个人化医疗

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球胆固醇检测市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品类型（测试套件、测试条、其他）
  • 按测试类型（总胆固醇测试、高密度脂蛋白 (HDL) 胆固醇、低密度脂蛋白 (LDL) 胆固醇、三酸甘油酯/VLDL 胆固醇测试）
  • 依处方模式（非处方药、处方药）
  • 按最终使用者（医院和诊所、诊断实验室、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美胆固醇检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲胆固醇检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太胆固醇检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美胆固醇检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲胆固醇检测市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Abbott Laboratories Inc.
• Beckman Coulter Inc.
• Horiba Ltd.
• Nova Biomedical Corp.
• Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• Randox Laboratories Ltd.
• Siemens Healthineers Gmbh
• Sekisui Diagnostics LLC
• Sinocare Inc.
• Thermo Fisher Scientific Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Cholesterol Testing Market was valued at USD 12.36 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.92% through 2030. A cholesterol test, also known as a lipid profile or lipid panel, is a vital medical examination used to assess the levels of various lipids-primarily cholesterol and triglycerides-in the bloodstream. This test typically measures total cholesterol, low-density lipoprotein (LDL or "bad" cholesterol), high-density lipoprotein (HDL or "good" cholesterol), and triglycerides. These values offer essential insights into a person's cardiovascular health and help identify potential risks for conditions such as coronary artery disease, heart attacks, and strokes. Elevated LDL levels and low HDL levels can increase the risk of plaque buildup in arteries, leading to restricted blood flow and serious heart complications. Routine cholesterol testing is particularly important for individuals with a family history of heart disease, those with diabetes, or people leading sedentary lifestyles with poor dietary habits. Early detection of abnormal cholesterol levels allows for timely lifestyle changes or medical interventions, such as adopting a healthier diet, increasing physical activity, or using cholesterol-lowering medications. Since cholesterol levels can be influenced by various factors-including age, genetics, diet, and overall health-it is essential to consult with a healthcare professional. They can interpret the results accurately and recommend personalized strategies for managing cholesterol and maintaining long-term cardiovascular wellness.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases, including heart attacks and strokes, often have subtle or asymptomatic early stages. For instance, according to a 2024 article, coronary artery disease (CAD) is a common yet serious heart condition that can lead to heart attacks. A recent study, published in the European Heart Journal, highlights that measuring apolipoprotein B particles and lipoprotein(a) levels may improve risk prediction for CAD. These lipoproteins carry "bad" cholesterol in the blood and play a critical role in plaque buildup in coronary arteries. The Centers for Disease Control and Prevention (CDC) states that CAD is caused by plaque accumulation in the arteries supplying blood to the heart, emphasizing the importance of early screening and preventive care. Cholesterol testing helps identify individuals with high cholesterol levels, who are at an increased risk of developing CVDs. Early detection allows for timely intervention and lifestyle changes that can help prevent or manage the progression of these diseases. Cholesterol testing provides valuable information for risk assessment and stratification. Individuals with elevated cholesterol levels are categorized as high-risk patients for CVDs. This categorization helps healthcare providers tailor treatment and management strategies, potentially preventing future cardiovascular events. For individuals diagnosed with CVDs or at risk of developing them, cholesterol testing is used to monitor the effectiveness of treatments such as medication, dietary changes, and exercise. Regular testing helps healthcare professionals adjust treatment plans as needed to achieve target cholesterol levels. The rising prevalence of cardiovascular diseases underscores the importance of cholesterol testing as a critical tool for prevention, early detection, and management. The increasing demand for cholesterol testing is a natural response to the need to address the growing burden of CVDs and their associated risk factors.

Key Market Challenges

Technological Limitations

While point-of-care testing devices and home testing kits have improved accessibility, their accuracy might not always match that of laboratory-based testing, potentially affecting diagnostic reliability. Point-of-care testing devices and home testing kits might yield results that can vary from one test to another or from laboratory-based measurements. This variability can lead to uncertainty in interpreting results and making clinical decisions. Home testing kits and point-of-care devices rely on individuals performing the test correctly. User errors, such as improper sample collection or incorrect device operation, can significantly impact the accuracy of results. Proper calibration and maintenance of testing devices are crucial for accuracy. Without regular calibration and quality control, point-of-care devices might drift from accurate results over time. Inaccurate results from point-of-care testing or home testing kits can impact clinical decision-making. Incorrect management strategies based on unreliable results might harm patient outcomes.

Key Market Trends

Personalized Medicine

The trend toward personalized medicine will likely extend to cardiovascular health. Cholesterol testing can provide essential data for tailoring interventions and treatment plans based on an individual's unique risk profile. The trend toward personalized medicine has the potential to greatly impact cardiovascular health, and cholesterol testing plays a vital role in this shift. Personalized medicine aims to provide individualized healthcare based on an individual's unique genetic makeup, lifestyle, and other factors. Cholesterol testing offers essential data that can help tailor interventions and treatment plans specifically for an individual's risk profile. Based on an individual's cholesterol levels, genetic factors, medical history, and other health metrics, healthcare providers can create personalized treatment plans. This might involve lifestyle modifications, medication choices, and specific targets for cholesterol levels. Personalized medicine involves continuous monitoring of an individual's health markers. Cholesterol testing serves as a valuable tool for tracking progress and ensuring that the chosen interventions are effective. Regular testing encourages patient adherence to treatment plans. For individuals who require cholesterol-lowering medications, personalized medicine can guide the choice of medications and dosages. Certain medications might be more effective or better tolerated based on an individual's genetic and metabolic factors.

Key Market Players

• Abbott Laboratories Inc.
• Beckman Coulter Inc.
• Horiba Ltd.
• Nova Biomedical
• Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• Randox Laboratories Ltd.
• Siemens Healthineers Gmbh
• Sekisui Diagnostics LLC
• Sinocare Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Cholesterol Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cholesterol Testing Market, By Product Type:

• Test Kits
• Test Strips
• Other

Cholesterol Testing Market, By Test Type:

• Total Cholesterol Test
• High-Density Lipoprotein (HDL) Cholesterol
• Low-Density Lipoprotein (LDL) Cholesterol
• Triglycerides/VLDL Cholesterol Test

Cholesterol Testing Market, By Prescription Mode:

• Over the Counter
• Prescription Based

Cholesterol Testing Market, By End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Cholesterol Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholesterol Testing Market.

Available Customizations:

Global Cholesterol Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholesterol Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type Type (Test Kits, Test Strips, Others)
  • 5.2.2. By Test Type (Total Cholesterol Test, High-Density Lipoprotein (HDL) Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, Triglycerides/VLDL Cholesterol Test)
  • 5.2.3. By Prescription Mode (Over the Counter, Prescription Based)
  • 5.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Cholesterol Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Test Type
  • 6.2.3. By Prescription Mode
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cholesterol Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Prescription Mode
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Cholesterol Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Prescription Mode
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Cholesterol Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Prescription Mode
      • 6.3.3.2.4. By End User

7. Europe Cholesterol Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Test Type
  • 7.2.3. By Prescription Mode
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cholesterol Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Prescription Mode
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Cholesterol Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Prescription Mode
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Cholesterol Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Prescription Mode
      • 7.3.3.2.4. By End User
  • 7.3.4. France Cholesterol Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Prescription Mode
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Cholesterol Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Prescription Mode
      • 7.3.5.2.4. By End User

8. Asia-Pacific Cholesterol Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Test Type
  • 8.2.3. By Prescription Mode
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cholesterol Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Prescription Mode
      • 8.3.1.2.4. By End User
  • 8.3.2. India Cholesterol Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Prescription Mode
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Cholesterol Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Prescription Mode
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Cholesterol Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Prescription Mode
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Cholesterol Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Prescription Mode
      • 8.3.5.2.4. By End User

9. South America Cholesterol Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Test Type
  • 9.2.3. By Prescription Mode
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cholesterol Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Prescription Mode
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Cholesterol Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Prescription Mode
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Cholesterol Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Prescription Mode
      • 9.3.3.2.4. By End User

10. Middle East and Africa Cholesterol Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Test Type
  • 10.2.3. By Prescription Mode
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cholesterol Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Prescription Mode
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Cholesterol Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Prescription Mode
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Cholesterol Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Prescription Mode
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Abbott Laboratories Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Beckman Coulter Inc.
• 14.3. Horiba Ltd.
• 14.4. Nova Biomedical Corp.
• 14.5. Roche Holding Ag (F.Hoffmann-La Roche Ltd.)
• 14.6. Randox Laboratories Ltd.
• 14.7. Siemens Healthineers Gmbh
• 14.8. Sekisui Diagnostics LLC
• 14.9. Sinocare Inc.
• 14.10. Thermo Fisher Scientific Inc.

15. Strategic Recommendations

16. About Us & Disclaimer